A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).

Trial Details

NCT ID

NCT05818683

Phase

PHASE1

Sponsor

Janssen Research & Development, LLC

Status

RECRUITING

Cancer Type

Hormone-Sensitive Prostate Cancer

Interventions

Pasritamig
Cetrelimab
Cabazitaxel
Docetaxel
Apalutamide
Enzalutamide

Locations (sample)

Sarasota, Florida, United States|27.33643,-82.53065
Grand Rapids, Michigan, United States|42.96336,-85.66809
St Louis, Missouri, United States|38.62727,-90.19789
Brooklyn, New York, United States|40.6501,-73.94958
Mineola, New York, United States|40.74927,-73.64068

Key Eligibility Criteria

Part 1 A-G, 1I, 1J, and 1K (all combination treatments) and Parts 2B-C (cabazitaxel, docetaxel): Metastatic castration-resistant prostate cancer (m…
Measurable or evaluable disease, except for Part 2H
(a) Part 1A (cetrelimab) - Prior treatment for mCRPC with at least 1 prior androgen receptor pathway inhibitors (ARPI) (that is, abiraterone acetat…
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →